Jørgen Schøler Kristensen explains the role of the Danish Medicines Council, providing guidance about new medicines for use in the Danish hospital sector. Kristensen also tackles the thorny issues of price considerations, assessing the long-term efficacy of innovative new therapies, and working collaboratively with private industry.
There is a necessity for collaboration between the healthcare sector and the industry. Without this collaboration, innovation will not occur, and new drugs will not make it to market, which will have a detrimental effect on patient outcomes
